EP3580355A4 - S100bêta et ses isoformes pour la détection d'affections neurologiques - Google Patents

S100bêta et ses isoformes pour la détection d'affections neurologiques Download PDF

Info

Publication number
EP3580355A4
EP3580355A4 EP18751838.6A EP18751838A EP3580355A4 EP 3580355 A4 EP3580355 A4 EP 3580355A4 EP 18751838 A EP18751838 A EP 18751838A EP 3580355 A4 EP3580355 A4 EP 3580355A4
Authority
EP
European Patent Office
Prior art keywords
isoforms
detection
neurological conditions
neurological
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18751838.6A
Other languages
German (de)
English (en)
Other versions
EP3580355A2 (fr
Inventor
Stephen F. LARNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioregency Inc
Original Assignee
Bioregency Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioregency Inc filed Critical Bioregency Inc
Publication of EP3580355A2 publication Critical patent/EP3580355A2/fr
Publication of EP3580355A4 publication Critical patent/EP3580355A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP18751838.6A 2017-02-07 2018-02-07 S100bêta et ses isoformes pour la détection d'affections neurologiques Pending EP3580355A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455787P 2017-02-07 2017-02-07
PCT/US2018/017244 WO2018148294A2 (fr) 2017-02-07 2018-02-07 S100bêta et ses isoformes pour la détection d'affections neurologiques

Publications (2)

Publication Number Publication Date
EP3580355A2 EP3580355A2 (fr) 2019-12-18
EP3580355A4 true EP3580355A4 (fr) 2020-12-16

Family

ID=63107818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18751838.6A Pending EP3580355A4 (fr) 2017-02-07 2018-02-07 S100bêta et ses isoformes pour la détection d'affections neurologiques

Country Status (4)

Country Link
EP (1) EP3580355A4 (fr)
JP (2) JP2020507622A (fr)
AU (1) AU2018219790B2 (fr)
WO (1) WO2018148294A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871467A1 (fr) * 2004-06-14 2005-12-16 Genoscreen Soc Par Actions Sim Proteine cog47 et polymorphisme du gene s100 beta
WO2009014342A2 (fr) * 2007-07-20 2009-01-29 Young In Frontier Co., Ltd. Marqueurs et kit de diagnostic de la maladie d'alzheimer
WO2010019553A2 (fr) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Procédé de détection de biomarqueurs et test d'état neurologique
WO2011144914A2 (fr) * 2010-05-21 2011-11-24 Universite De Geneve Méthodes de diagnostic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667672A4 (fr) * 2003-10-03 2010-02-10 Ono Pharmaceutical Co Procede de prevention et/ou de traitement de maladies neurodegeneratives
AU2010291933B2 (en) * 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
WO2014194329A1 (fr) * 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. Marqueur neuronal spécifique s100β pour dosages de biomarqueurs et dispositifs utilisés dans la détection d'une affection neurologique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871467A1 (fr) * 2004-06-14 2005-12-16 Genoscreen Soc Par Actions Sim Proteine cog47 et polymorphisme du gene s100 beta
WO2009014342A2 (fr) * 2007-07-20 2009-01-29 Young In Frontier Co., Ltd. Marqueurs et kit de diagnostic de la maladie d'alzheimer
WO2010019553A2 (fr) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Procédé de détection de biomarqueurs et test d'état neurologique
WO2011144914A2 (fr) * 2010-05-21 2011-11-24 Universite De Geneve Méthodes de diagnostic

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARATEIRO ANDREIA ET AL: "S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 53, no. 6, 17 July 2015 (2015-07-17), pages 3976 - 3991, XP036249031, ISSN: 0893-7648, [retrieved on 20150717], DOI: 10.1007/S12035-015-9336-6 *
DATABASE Geneseq [online] 23 February 2006 (2006-02-23), "Human Cog47 protein SEQ ID NO:1.", XP055747735, retrieved from EBI accession no. GSP:AEE63197 Database accession no. AEE63197 *
GONCALVES C A ET AL: "Biological and methodological features of the measurement of S100B, a putative marker of brain injury", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 41, no. 10-11, 1 July 2008 (2008-07-01), pages 755 - 763, XP022732684, ISSN: 0009-9120, [retrieved on 20080418], DOI: 10.1016/J.CLINBIOCHEM.2008.04.003 *
HEIZMANN C W ET AL: "S100 proteins: structure, functions and pathology", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 7, 1 May 2002 (2002-05-01), pages d1356 - d1368, XP002394878, ISSN: 1093-9946 *

Also Published As

Publication number Publication date
JP2023017805A (ja) 2023-02-07
JP2020507622A (ja) 2020-03-12
CA3052636A1 (fr) 2018-08-16
JP7597770B2 (ja) 2024-12-10
AU2018219790A1 (en) 2019-08-22
AU2018219790B2 (en) 2024-10-10
WO2018148294A2 (fr) 2018-08-16
EP3580355A2 (fr) 2019-12-18

Similar Documents

Publication Publication Date Title
SG11202104501UA (en) Systems and methods for the treatment of eye conditions
EP3247708A4 (fr) Composés et procédés pour la dégradation ciblée du récepteur des androgènes
EP3270917A4 (fr) Composés et procédés de dégradation accrue de protéines ciblées
EP3194014A4 (fr) Casque pour la neurostimulation et la détection de paramètres corporels
EP3212137A4 (fr) Systèmes et procédés pour le traitement d'affections oculaires
EP3723762A4 (fr) Inhibiteurs de la voie de réponse intégrée au stress
EP4022066A4 (fr) Procédés et systèmes d'évaluation du risque de troubles d'utilisation d'une substance
EP3638808A4 (fr) Détection de régions de séquence ciblées
PT3297628T (pt) Azasetron para uso no tratamento de perda auditiva
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
EP3310783A4 (fr) Procédés et compositions de prévention et de traitement de la perte d'audition
EP3319564B8 (fr) Dispositif de grattoir ophtalmique et procédé de fabrication de celui-ci
EP3684383A4 (fr) Méthodes et systèmes destinés à la détection de troubles tissulaires
EP3371154A4 (fr) Dérivés hétérocycliques et leur utilisation pour le traitement de troubles du snc
EP3580355A4 (fr) S100bêta et ses isoformes pour la détection d'affections neurologiques
EP3298159A4 (fr) Procédés pour augmenter l'extraction d'enzymes d'aliment pour animaux et pour mesurer leur activité
HK40071463B (en) Antisense oligomers for treatment of conditions and diseases
HK40064034B (en) Antisense oligomers for treatment of conditions and diseases
EP3256144A4 (fr) Inhibition peptidique des maladies ou affections médiées par le ccr3
HK40031149A (en) Compounds and methods for the targeted degradation of androgen receptor
HK40032684A (en) Antisense oligomers for treatment of conditions and diseases
HK40033359A (en) Interleukin-18 variants and methods of use
HK40012950A (en) Methods and processes for assessment of genetic variations
AU2018902206A0 (en) Methods and systems for assessing the risk of glaucoma
AU2017905098A0 (en) Method of treating or preventing neurological diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201118

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6883 20180101ALI20201112BHEP

Ipc: C07K 16/18 20060101ALI20201112BHEP

Ipc: C12Q 1/68 20180101AFI20201112BHEP

Ipc: G01N 33/68 20060101ALI20201112BHEP

Ipc: G01N 33/564 20060101ALI20201112BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231124